Conference call to discuss the strategic collaboration with Amgen

Stockholm, 4 October, 2016. Nuevolution AB (publ) (NUE.ST) announce that the
company’s executive management will host a conference call and webcast to
discuss the strategic collaboration with Amgen on Tuesday 4 October at 14:00
CEST. Access to the event can be obtained as follows:

LIVE access on Tuesday 4 October at 14:00 CEST

Telephone numbers:

SE: +46 85 664 2662

DK: +45 3544 5575

UK: +44 20 3008 9808

US: +1 855 7532 235

Webcast will be available at www.nuevolution.com in the Investors section and at
www.financialhearings.com

REPLAY access

Webcast replay will be available at www.nuevolution.com in the Investors section
and at www.financialhearings.com

For more information, please contact:

Alex Haahr Gouliaev

Chief Executive Officer

Nuevolution AB (publ)

Phone: +45 7020 0987

Email: ahg@nuevolution.com

Henrik D. Simonsen

Chief Financial Officer

Nuevolution AB (publ)

Phone: +45 3913 0947

Email: hs@nuevolution.com

About Nuevolution

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company
founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its
proprietary discovery platform and programs with pharmaceutical and
biotechnology companies to seek future benefit of patients in need of novel
medical treatment options. Nuevolution’s internal programs are focused on
therapeutically important targets within inflammation, oncology and immuno
-oncology.

This information is information that Nuevolution AB (publ) is obliged to make
public pursuant to the Securities Market Act. The information was sent for
publication on Tuesday 4 October, 10:00 (CEST).

Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm,
Sweden (ticker: NUE.ST). Västra Hamnen Corporate Finance AB acts as Certified
Adviser to Nuevolution AB (publ). More information about Nuevolution can be
found on: www.nuevolution.com